EACS2023: 32 Screening of HPV-related anogenital cancers in women living with HIV in Europe: results from a systematic review D.C. Krankowska , M. Mazzitelli , H. Albayrak , E. Orviz , H. nur Karakoç , H. Mortimer , K. Aebi-Popp , Y. Gilleece Medical University of Warsaw, Hospital for Infectious Diseases, Department of Infectious and Tropical Diseases and Hepatology, Warsaw, Poland, Padua University Hospital, Infectious and Tropical Diseases Unit, Padua, Italy, CPL Life Science, Hurley, United Kingdom, Centro Sanitario Sandoval, Hospital Clinico San Carlos, Madrid, Spain, Karadeniz Technical University School of Medicine, Trabzon, Turkey, Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom, Bern University Hospital, University of Bern, Department of Infectious Diseases and Department of Obstetrics and Gynecology, Bern, Switzerland General data Abstract category: Access and delivery of care Abstract body Purpose: Women living with HIV (WLWH) are at increased risk of HPV-related cancers. Throughout Europe, there is heterogeneity among screening programs, access to HPV testing and HPV vaccination. This review aims to summarize available data on screening and prevention measures for HPV-related ano-genital cancers in WLWH across the WHO European Region (WER). Method: The systematic review followed the PRISMA guidelines and was registered on Prospero. Pubmed, Embase and Web of Science databases were searched to identify available studies, written in English, and published between 2011 and 2021. A metanalysis was conducted using random-effects models to calculate pooled prevalence of HPV. Subgroup analyses were conducted according to country and HPV testing. Results: Thirty-four articles involving 10,336 WLWH met the inclusion criteria. Studies were heterogenous in their methodology and presentation of results: 73.5% studies focused on cervical cancer prevention, 4.4% on anal cancer. 76.5% studies conducted HPV testing as part of screening. The prevalence of hr-HPV was 30.5-33.9%. 77% of WLWH had cervical cytology results reported. Six studies reported a positive association of CD4+ cell count <200/mm with HPV prevalence and cervical abnormalities. Anal HPV testing was conducted in <8% of participants. HPV vaccination was completed in 5.6% of women with known vaccination status. There was no information about the vaccination status of the majority of women in the analyzed studies. Conclusions: Data about screening of HPV-related anogenital cancer in WLWH in Europe are heterogenous and lacking, especially about anal cancer. HPV DNA testing is not routinely done as part of screening for HPV-related cancer. Low CD4+ cell count is a risk factor for HPV infection and cytological abnormalities. HPV vaccination data is poor and vaccination rates are very low among WLWH in Europe. This review concludes that significant improvements are required for data and consistency on guidelines for HPV screening, prevention and vaccination in WLWH. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 6 1 2 3 4 5 6 7 3 5
RkJQdWJsaXNoZXIy Mzc2ODc=